TRMK Q1 Deep Dive: Loan Growth, Expense Control, and Cautious Outlook on Tariffs and Rates
Is now the time to buy TRMK? Find out in our full research report (it's free).
Revenue: $194.6 million vs analyst estimates of $193.6 million (3.4% year-on-year growth, 0.5% beat)
Adjusted EPS: $0.88 vs analyst estimates of $0.82 (7.8% beat)
Market Capitalization: $2.06 billion
Trustmark's first quarter performance was defined by continued loan growth, stable credit quality, and disciplined expense management, as highlighted by CEO Duane Dewey. Management pointed to diversified loan increases across commercial real estate, other commercial segments, and mortgage lending, while also noting a modest decline in non-interest expenses. CFO Tom Owens credited the net interest margin's stability to ongoing repricing of the fixed-rate loan book and securities portfolio, while Chief Credit and Operations Officer Barry Harvey emphasized that net charge-offs and provisions remained in line with expectations, with no major surprises in credit quality during the quarter.
Looking ahead, Trustmark reaffirmed its full-year 2025 expectations for low single-digit loan and deposit growth, citing ongoing uncertainty from tariffs and interest rate policies. Dewey acknowledged early signs of cautious client behavior following recent tariff developments, noting, 'We could see some slowdown in some of that new origination volume that we were anticipating.' Management remains watchful of changing market sentiment, while continuing to prioritize organic loan growth and potential expansion into high-growth markets such as Houston, Birmingham, and the Gulf Coast. The company expects disciplined capital deployment, including opportunistic share repurchases, to remain a focus as the year progresses.
Management attributed first quarter results to broad-based loan growth, lower expenses, and ongoing stability in credit quality, while also acknowledging emerging external uncertainties.
Diversified loan growth: Loan balances increased across commercial real estate (CRE), commercial, and mortgage segments. Harvey explained that many CRE borrowers are choosing to extend maturing loans due to rate uncertainty, which has deferred expected payoffs and supported loan growth in the quarter.
Deposit base stability: CFO Tom Owens noted stable personal and commercial deposit balances, with the cost of total deposits declining 15 basis points. The company continues to optimize deposit pricing without relying on promotional rates, which Owens indicated gives 'good flexibility' for supporting future loan growth.
Expense management focus: Non-interest expenses declined slightly, driven by lower salaries, benefits, and commissions. Dewey credited slower hiring and production in areas like mortgage banking as key drivers, and highlighted ongoing efforts to control expenses despite some planned increases later in the year, including a core system conversion.
Credit quality maintained: Net charge-offs and provisions remained near historical norms, with Harvey noting a modest provision increase driven by loan growth and updated risk ratings. The allowance for credit losses was adjusted upward, but management described overall credit trends as stable.
Strategic capital deployment: The company repurchased $15 million of stock during the quarter and has $85 million of remaining authorization. Dewey indicated that capital deployment decisions—including buybacks and potential M&A—will depend on market conditions and ongoing loan growth, with organic expansion in select high-growth markets as a priority.
Trustmark's guidance for the year is shaped by external economic uncertainty, evolving customer behavior, and a focus on expense discipline and market expansion.
Tariffs and policy impacts: Management is closely monitoring the effects of recently announced tariffs and administrative policies, acknowledging that clients are beginning to show caution in new borrowing decisions. Dewey noted that while loan origination pipelines remain solid, 'we could see some slowdown' if uncertainty persists.
Interest rate sensitivity: The company's net interest margin outlook depends on the future path of Federal Reserve rate cuts. Owens explained that, assuming two cuts this year, the margin is expected to improve slightly through ongoing repricing of loans and securities. However, a faster-than-expected decline in rates could limit margin expansion.
Expense growth and investment: Planned expenses later in the year, including merit increases and technology investments like a core system conversion, are expected to drive mid-single-digit expense growth. Management aims to offset these increases through continued expense discipline, with Chambers noting that merit increases are now timed for the third quarter, impacting the expense trajectory.
Moving forward, the StockStory team will be watching (1) signs of changing client demand and loan origination volumes in response to tariffs and rate uncertainty, (2) the pace and impact of planned investments such as the core system conversion on expense growth, and (3) the company's ability to maintain stable credit quality as competitive pressures increase and economic conditions evolve. Progress in market expansion initiatives and capital deployment strategies will also be important to monitor.
Trustmark currently trades at $34.66, down from $35.82 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it's free).
Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J., August 01, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300,000 restricted shares of the Company's common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Kalbermatten and the Company. The Compensation Committee of the Company's Board of Directors approved the awards as an inducement material to Mr. Kalbermatten's employment in accordance with Nasdaq Listing Rule 5635(c)(4). About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the "Freedom System") currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit View source version on Contacts Investor Contact: Louisa Smithinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
21 minutes ago
- Business Wire
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) ('KORU Medical' or the 'Company'), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300,000 restricted shares of the Company's common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Kalbermatten and the Company. The Compensation Committee of the Company's Board of Directors approved the awards as an inducement material to Mr. Kalbermatten's employment in accordance with Nasdaq Listing Rule 5635(c)(4). About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the 'Freedom System') currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit


Hamilton Spectator
21 minutes ago
- Hamilton Spectator
Wall Street falls the most since May after employers slash hiring and tariffs roll out
The U.S. stock market had its worst day since May on Friday after the government reported a sharp slowdown in hiring and President Donald Trump imposed sweeping tariffs on imports from a number of U.S. trading partners. The S&P 500 fell 1.6%, its biggest decline since May 21 and its fourth straight loss. The index is also posted a 2.4% loss for the week, marking a sharp shift from last week's record-setting streak of gains. The Dow Jones Industrial Average fell 1.2%, while the Nasdaq composite fell 2.2%. Worries on Wall Street about a weakening economy were heavily reinforced by the latest report on job growth in the U.S. Employers added just 73,000 jobs in July. That is sharply lower than economists expected. The Labor Department also reported that revisions shaved a stunning 258,000 jobs off May and June payrolls. Markets also reacted to the latest tariff news . President Donald Trump announced tariff rates on dozens of countries and pushed back the scheduled effective date to Aug. 7, adding more uncertainty to the global trade picture.